United Therapeutics (UTHR) announced full enrollment of the TETON 1 study evaluating the use of Tyvaso or treprostinil, inhalation solution or ...

On February 3rd, our Board of Directors approved another tax-efficient share repurchase program of up to 10% of our total shares outstanding, expected to be executed over the next three to six months.

Air pollution is a well-known risk factor for respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).